Federated Hermes
SPRY icon

Federated Hermes’s ARS Pharmaceuticals SPRY Stock Holding History

Federated Hermes’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-473
Closed -$4.99K – 2190
2024
Q4 		$4.99K Buy
+473
New +$6.63K ﹤0.01% 1896
2024
Q2 		– Sell
-169
Closed -$1.73K – 2128
2024
Q1 		$1.73K Buy
+169
New +$1.26K ﹤0.01% 1932
2023
Q4 		– Sell
-707
Closed -$2.67K – 2192
2023
Q3 		$2.67K Buy
+707
New +$4.64K ﹤0.01% 1943
2022
Q4 		– Sell
-2,220
Closed -$12K – 2273
2022
Q3 		$12K Buy
2,220
+1,925
+653% +$9.49K ﹤0.01% 1816
2022
Q2 		$1K Buy
+295
New +$1.03K ﹤0.01% 2078

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Federated Hermes's SPRY Position: Q1 2025 in Review

Federated Hermes sold out of ARS Pharmaceuticals (SPRY) in Q1 2025, closing a stake of 473 shares — an estimated $4.99K sold.

Federated Hermes first reported a position in SPRY in Q2 2022 and held it in 5 quarters. The position peaked at $12K in Q3 2022. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

  • Federated Hermes reported no remaining ARS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Federated Hermes sold 473 ARS Pharmaceuticals shares in Q1 2025, an estimated $4.99K.
  • Federated Hermes first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Federated Hermes's ARS Pharmaceuticals position peaked at $12K in Q3 2022.
  • 184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Federated Hermes's 13F filing for Q1 2025, filed 8 May 2025.